Evommune reports Q4/FY2025 net loss $28.3M/$68.9M; positive EVO301 Ph2a data; $125M raise

Evommune, Inc.

Q4 net loss $28.3M; FY net loss $68.9M vs $66.8M prior year. Revenue $13.0M FY (Maruho deal). Cash $216.7M at Dec 31, 2025.
Positive Phase 2a POC data for EVO301 in atopic dermatitis: met primary endpoint, 33% placebo-adjusted EASI reduction at week 12 after 2 doses.
EVO756 Phase 2b top-line data expected 2Q26 for CSU, 2H26 for AD; Phase 2b in migraine to start mid-2026.
Closed $125M private placement in Feb 2026; cash runway extended through 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.